Yongjun Zhu

Yongjun Zhu

Auto-generated profile, based on publicly available information

Yongjun Zhu

Chongqing Med Univ, Affiliated Hosp 2, Dept Gastroenterol & Hepatol, Chongqing, Peoples R China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
LYLi Yang
Li Yang
XWXiaoze Wang
Xiaoze Wang
XXXiaotan Xi
Xiaotan Xi
XLXiao Li
Xiao Li
XLXuefeng Luo
Xuefeng Luo
LYLi Yang
Li Yang

12 January 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
YYYuling Yan
Yuling Yan
XXXian Xing
Xian Xing
XWXiaoze Wang
Xiaoze Wang
RMRuoting Men
Ruoting Men
XLXuefeng Luo
Xuefeng Luo
LYLi Yang
Li Yang
Background A large portion of patients with compensated advanced chronic liver disease (cACLD) do not have varices or only have low risk varices. Aims To create and validate an easy-to-use risk scoring system to identify high-risk varices (HRV) and spare esophagogastroduodenoscopy (EGD) in patients with hepatitis B virus (HBV)-related cACLD. Methods In total, 334 patients with HBV-related cACLD who had undergone routine laboratory tests and ultrasound examination were enrolled. Multivariate logistic regression analysis was used to determine which variables were the independent risk factors for the presence of HRV, so as to establish the scoring system for screening HRV. The criteria were tested in a training cohort with 221 patients and validated in a validation cohort with 113 patients. Results In the training cohort, the prevalence of HRV was 29.5%. Albumin (ALB) [OR 0.83; 95% confidence index (CI) 0.77–0.90; P < 0.0001], platelet count (PLT) (OR 0.96, 95% CI 0.96–0.99; P < 0.0001) and portal vein diameter (OR 1.40; 95% CI 1.15–1.71; P = 0.001) were independent risk factors for the presence of HRV. The negative predictive value was > 95%, when albumin-platelet-portal vein diameter varices scores (APP score) were < 0.24. One hundred twenty-five of 221 (56.6%) patients met an APP score < 0.24 with a 4.8% HRV miss rate. In the validation cohort, 59 of 113 (51.3%) patients met the APP score < 0.24 with a 1.7% HRV miss rate. Conclusions APP score is a potential model for safely screening HRV and sparing EGDs in patients with HBV-related cACLD.

11 February 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
PWPing Wang
Ping Wang
ZXZhen Xiong
Zhen Xiong
FYFang Yang
Fang Yang
WCWei Cai
Wei Cai
GWGuo-Xiang Wang
Guo-Xiang Wang
LYLi Yang
Li Yang

5 March 2021 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
XWXiaoze Wang
Xiaoze Wang
LYLi Yang
Li Yang
MZMing Zhao
Ming Zhao
XLXuefeng Luo
Xuefeng Luo
LYLi Yang
Li Yang
PURPOSE We aimed to determine the technical feasibility, safety and prognosis of the transjugular intrahepatic portosystemic shunt (TIPS) revision by combined Y-configured stents placement. METHODS We retrospectively evaluated 12 patients who received TIPS revision using Y-stenting technique between June 2015 and January 2019. The rates of technical success, complication, shunt patency, hepatic encephalopathy and mortality were described and analyzed. RESULTS The combined Y-configured stents were successfully placed in 11 of 12 patients (92%) without major complications. The median portosystemic pressure gradient (PPG) decreased from 23 mmHg (interquartile range, IQR, 18.5-27.5 mmHg) to 10 mmHg (IQR, 9-14 mmHg). The left internal jugular vein approach was used in 5 patients. Four patients required a shunt extension with an extra stent to resolve the stenosis at the portal venous terminus. Two patients developed hepatic encephalopathy, which was medically controlled within 3 months after the procedure. The TIPS patency and survival rates were both 100% during a median follow-up period of 10 months (IQR, 5.5-14 months). CONCLUSION TIPS revision by combined Y-configured stents placement was technically feasible and safe with favorable clinical outcomes.